The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAssura Regulatory News (AGR)

Share Price Information for Assura (AGR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.62
Bid: 41.66
Ask: 41.72
Change: -0.02 (-0.05%)
Spread: 0.06 (0.144%)
Open: 41.60
High: 42.34
Low: 41.38
Prev. Close: 41.64
AGR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

18 Jul 2017 07:00

RNS Number : 3424L
Assura PLC
18 July 2017
 

Assura plc

 

Trading Update

For the first quarter to 30 June 2017

 

Continued strong growth

 

Assura plc ("Assura"), the UK's leading primary care property investor and developer, today publishes a trading update for the first quarter to 30 June 2017.

 

Value enhancing investment activity

 

Assura continued to make good progress in the first quarter, completing the acquisition of 24 medical centres for a gross consideration of £48.9 million with an aggregate passing rent roll of £2.5 million and a weighted average unexpired lease length of 13.1 years.

 

Assura has a further pipeline of individual asset acquisitions and developments currently in solicitors' hands worth approximately £146 million, of which £76 million represent acquisitions and £70 million are developments.

 

Rental income increased

 

Assura now owns 422 medical centres with a total annualised rent roll of £76.9 million (31 March 2017: £74.4 million), with growth in the financial year to date driven primarily by acquisitions.

 

The weighted average annual rent increase was 2.07% based on 36 reviews settled in the three months to 30 June 2017, of which the average annual rent increase derived from open market rent reviews was 1.25%.

 

Strong financing and debt position

 

On 20 June 2017, the Company raised £98 million gross of expenses in an equity placing equivalent to approximately 9.9% of the pre-existing ordinary share capital. Following this equity issuance, as at 30 June 2017 Assura's undrawn facilities were £160 million and proforma net loan to value ratio was 33%.

 

Jonathan Murphy, CEO, commented:

 

"We were pleased with the investor support for our recent equity issue, which was significantly oversubscribed, and this allows us to build on our leading position in the sector by taking advantage of the opportunities in the market while also maintaining a strong balance sheet. Despite the uncertain political landscape there remains support across the UK political spectrum for further investment in primary care premises, and Assura is well placed to help plans become reality in a market that is in critical need of investment."

 

For more information, please contact:

 

Assura plc

 

Tel: 01925 420660

Jonathan Murphy

 

Finsbury

 

Tel: 0207 251 3801

Gordon Simpson

 

Notes to Editors

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create innovative property solutions to facilitate delivery of high quality patient care in the community. At 31 March 2017, Assura's property portfolio was valued at £1,345 million.

 

Further information is available at www.assuraplc.com

 

*EPRA is a registered trademark of the European Public Real Estate Association

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLIFSEDTITLID
Date   Source Headline
1st May 20242:30 pmRNSHolding(s) in Company
1st May 20247:00 amRNSNotice of Year End Results
30th Apr 20247:00 amRNSTotal Voting Rights
16th Apr 20247:40 amRNSDirector/PDMR Shareholding
8th Apr 20244:34 pmRNSDirector/PDMR Shareholding
8th Apr 20247:00 amRNSScrip Dividend Declaration
22nd Mar 20242:18 pmRNSHolding(s) in Company
14th Mar 20248:30 amRNSScrip Calculation Price
6th Mar 20241:26 pmRNSDirector/PDMR Shareholding
29th Feb 20247:00 amRNSNotice of Dividend
8th Feb 20242:00 pmRNSCapital Markets Event
7th Feb 20242:33 pmRNSDirector/PDMR Shareholding
1st Feb 20249:32 amRNSTotal Voting Rights
16th Jan 20248:26 amRNSDirector/PDMR Shareholding
10th Jan 20247:00 amRNSTrading Update
9th Jan 20248:59 amRNSDirector/PDMR Shareholding
8th Jan 20247:00 amRNSScrip Dividend Declaration
21st Dec 20234:20 pmRNSDirector/PDMR Shareholding
14th Dec 20237:00 amRNSScrip Calculation Price
6th Dec 20232:57 pmRNSDirector/PDMR Shareholding
30th Nov 20237:00 amRNSNotice of Dividend
16th Nov 20237:00 amRNSAssura Plc Interim Results
8th Nov 20232:32 pmRNSDirector/PDMR Shareholding
1st Nov 20237:00 amRNSAppointment of Board Fellow
31st Oct 20237:00 amRNSNotice of Interim Results
31st Oct 20237:00 amRNSTotal Voting Rights
16th Oct 20232:04 pmRNSDirector/PDMR Shareholding
9th Oct 202311:13 amRNSDirector/PDMR Shareholding
9th Oct 20238:11 amRNSScrip Dividend Declaration
9th Oct 20237:00 amRNSRefinancing of RCF & new sustainability linkage
9th Oct 20237:00 amRNSTrading Update
18th Sep 20239:51 amRNSVesting and sale of restricted shares
14th Sep 20239:20 amRNSScrip Calculation Price
31st Aug 20237:00 amRNSNotice of Dividend
24th Aug 20238:36 amRNSHolding(s) in Company
8th Aug 20235:05 pmRNSDirector/PDMR Shareholding
31st Jul 20239:57 amRNSTotal Voting Rights
24th Jul 20237:00 amRNSDevelopment update
14th Jul 20231:47 pmRNSDirector/PDMR Shareholding
13th Jul 20234:47 pmRNSExercise of Nil Cost Options under PSP
12th Jul 20234:36 pmRNSDirector/PDMR Shareholding
10th Jul 202312:38 pmRNSHolding(s) in Company
10th Jul 20239:20 amRNSHolding(s) in Company
10th Jul 20237:00 amRNSScrip Dividend Declaration & Additional Listing
6th Jul 20232:47 pmRNSResult of AGM
6th Jul 202312:28 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSTrading Update
3rd Jul 20237:00 amRNSChange of Registered Office
29th Jun 20234:46 pmRNSHolding(s) in Company
29th Jun 20237:00 amRNSCompletion of 100th development

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.